Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens.

Safeguarding patients from emerging infectious diseases demands strategies that prioritise patient well-being and protection. Immunobridging is an established trial methodology which has been increasingly employed to ensure patient protection and provide clinicians with swift access to vaccines. It uses immunological markers to infer the effectiveness of a new drug through a surrogate measure of efficacy.

Ultraviolet radiation vs air filtration to mitigate virus laden aerosol in an occupied clinical room.

Mitigation measures against infectious aerosols are desperately needed. We aimed to: 1) compare germicidal ultraviolet radiation (GUV) at 254 nm (254-GUV) and 222 nm (222-GUV) with portable high efficiency particulate air (HEPA) filters to inactivate/remove airborne bacteriophage ϕX174, 2) measure the effect of air mixing on the effectiveness of 254-GUV, and 3) determine the relative susceptibility of ϕX174, SARS-CoV-2, and Influenza A(H3N2) to GUV (254 nm, 222 nm). A nebulizer generated ϕX174 laden aerosols in an occupied clinical room (sealed-low flow).

A Mixed Methods Approach to Korean-Youth Mental Health First Aid (K-YMHFA): A Pilot Study.

Purpose: Korean immigrant families are growing in the Southern United States (U.S), an area where culturally specific resources can be limited. Korean immigrant families encounter distress in navigating the American culture, but cultural stigma impedes discussion within the family.

Prognostic significance of diagnosis-to-surgery interval in oral cavity squamous cell carcinoma: A nationwide study.

Background: The question as to whether prolonged diagnosis-to-surgery intervals (DSIs) may compromise survival outcomes in patients with oral cavity squamous cell carcinoma (OCSCC) remains unanswered. This nationwide study was designed to address this issue.

Methods: We analyzed data from 26,214 patients with first primary OCSCC identified in the Taiwanese Cancer Registry Database between 2011 and 2021.